Full-Time

Director – Government Partnership Development

Ginkgo Bioworks

Ginkgo Bioworks

501-1,000 employees

Platform for cell programming and engineering

Compensation Overview

$170.1k - $273.5k/yr

+ Stock Awards

No H1B Sponsorship

Boston, MA, USA + 2 more

More locations: Washington, DC, USA | Oakland, CA, USA

Hybrid

Quarterly travel to the Boston, MA office is required.

US Top Secret Clearance Required

Bachelor's, Master's, PhD

Category
Business & Strategy (1)

Get referred to Ginkgo Bioworks

See people who can refer or advise you

Requirements
  • Bachelor’s degree with minimum of 8-10 years of relevant work experience in U.S. Government business development and acquisition
  • Understanding of the biotechnology industry and its applications and understanding of HHS and DOW contracting and decision making
  • Understanding of USG acquisition regulations and processes and budgeting processes
  • Demonstrated technical aptitude for complex, new, and disruptive products and services
  • Experience with complex deal structures
  • Enthusiasm about advancing Ginkgo’s mission to make biology easier to engineer
  • Ability to work effectively with cross-functional teams and mobilize people across the organization, and to learn quickly and thrive in a fast-paced environment
  • Strong aptitude for cultivating working relationships at all levels of management, both internally and externally
  • Organized and robust project management skills
Responsibilities
  • Plans and implements business development strategy for HHS, DOW, and related government agencies to drive bookings growth within the federal market and expand Ginkgo’s brand awareness and influence among Government customers
  • Lead the sales cycle for Ginkgo's automation products and services (RACs and RAC software) to wet labs within USG agencies, specifically targeting HHS and DoW
  • Craft innovative white papers, proposals, and pitches aimed at Government leadership with a focus on the value proposition of Ginkgo’s end-to-end lab automation service products and Solutions and Datapoints services
  • Create and shape business opportunities with the HHS, DOW, and other OneHealth-focused Government agencies, as well as with leading private sector government-focused entities, via both teaming efforts and direct sales, with a focus on top of the funnel activities
  • Lead Gov-funded pharma pipeline development and management activities
  • Map complex decision making processes, identify funding and award trends
  • Build a core set of strategic partnerships with industry, academic, and nonprofit organizations
  • Provide feedback/inputs to technical teams to support the development of new services/offerings and automation product features based on customer feedback.
  • Work jointly with Ginkgo’s U.S. Government partners to identify and scope out new project opportunities where Ginkgo is uniquely positioned to act as a valuable partner
  • Collaborate with partners to understand their program objectives and desired capabilities, including automation needs, and ensure that this context is incorporated into Ginkgo’s project scoping and delivery
  • Connect BD activities to U.S. Government solicitations such as RFPs, BAAs, FOAs, etc.
  • Be the voice of the customer during proposal development and reviews
  • Support the development of technical proposal materials and ensure the customer’s needs are incorporated
  • Support proposal development activities including writing content and participating in reviews
  • Scout for complementary partners, collaborators, and technologies and establish teaming relationships with them
  • Work across Ginkgo to ensure all parts of the organization are aligned during the business development process, and oversee and track the progress of projects and their execution to ensure high quality and timely deliverables
  • Collaborate with Ginkgo’s executive leadership and senior management team to define the company’s strategic goals for its U.S. Government HHS and DOW initiatives
Desired Qualifications
  • Master’s degree or PhD in science or technical field
  • 10+ years experience working with medical USG advanced developers
  • Previous experience with federal sales of lab automation equipment, specifically fully automated platforms, robotics, or liquid handling systems, to Government and/or commercial wet labs.
  • Transitioned one MCM product to market as either the prime contractor, subcontractor, or project manager
  • Strong existing relationships with leadership personnel at BARDA, ASPR, NIH, DHA, ARPA-H, USDA, DARPA, DTRA and other federal agencies focusing on OneHealth
  • Experience in technology development with government partners, in areas such medical countermeasures, cell lines and/or CBRNE defense
  • Ability and willingness to obtain a US security clearance at the Secret designation or above

Ginkgo Bioworks offers a platform-based approach to cell programming for diverse industries such as food, agriculture, pharma, and chemicals. Its Foundry is an automated lab system that designs, builds, and tests engineered organisms, while the Codebase is a growing library of genetic parts and experimental data that informs new projects, all tied together by a Design-Build-Test-Learn loop for fast prototyping. The company earns revenue from Foundry-based R&D services and from Downstream Value, which can include royalties, milestone payments, or equity in partner companies. Its goal is to make biology easier to engineer and speed up the development of biological products through end-to-end tooling and data-driven workflows.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

2009

Get referred to Ginkgo Bioworks

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • April 3, 2026 Perimeter spin-off and $60 million proceeds sharpened focus on autonomy.
  • Invaio's February 18, 2026 crop-protection deal expands Ginkgo into agricultural manufacturing.
  • Ginkgo cut 2026 first-half cash burn to $93 million and held $389 million liquidity.

What critics are saying

  • Q2 2026 revenue fell 48% to $20 million, exposing weak commercial demand.
  • Management gave no revenue guidance on August 5, 2026, hiding autonomous-lab adoption speed.
  • At $125 million-$150 million 2026 cash burn, Ginkgo risks existential dilution before traction.

What makes Ginkgo Bioworks unique

  • Ginkgo's Nebula and Cloud Lab turn wet labs into software-managed infrastructure.
  • OpenAI's GPT-5 collaboration on February 5, 2026 validated autonomous experimentation at scale.
  • The company bundles robotics, software, and strain libraries across pharma, agriculture, and industrial biology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Unlimited paid time off

Comprehensive health and parental leave benefits

Flexible work options

Commuter benefits

State-of-the-art labs, work spaces, and conference rooms

Competitive 401K contribution

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

2%

2 year growth

0%
Yahoo Finance
May 10th, 2026
Ginkgo Bioworks pivots to autonomous labs as Q1 revenue falls 49% to $19M

Ginkgo Bioworks is refocusing on autonomous laboratories following the divestiture of its biosecurity business, which closed on 3 April. The biosecurity spin-off created a new company called Perimeter and brought in $60 million, with Ginkgo retaining a shareholding. CEO Jason Kelly said the company's 2026 investment priorities centre on winning the autonomous lab category through running services on its Boston-based Nebula system and selling autonomous lab systems to early adopters like Pacific Northwest National Laboratory. First-quarter revenue from continuing operations fell 49% year-over-year to $19 million, though excluding a $7.5 million non-cash item from 2025, the decline was 37%. Operating expenses dropped significantly, with research and development costs down 38% to $30 million and general and administrative expenses falling 35% to $13 million.

Yahoo Finance
Mar 15th, 2026
Ginkgo Bioworks price targets cut as analysts split on automation lab rollout and cash burn

Analysts have trimmed price targets on Ginkgo Bioworks, with bullish views dropping to $12 from $14 and bearish targets falling to $5 from $9. The revisions reflect mixed sentiment around execution risk and recent business changes. TD Cowen maintained a Buy rating at $12, citing multi-year growth frameworks and improving investor sentiment ahead of 2026 guidance updates. BTIG kept its Sell rating at $5, noting it wants better visibility into how Ginkgo will monetise autonomous labs following the biosecurity business divestiture. Ginkgo recently launched Ginkgo Cloud Lab, a browser-based platform for running benchwork on autonomous lab infrastructure. The company announced collaborations with OpenAI on GPT-5-based biological experiments and with Invaio Sciences on microbial strains for crop protection.

PR Newswire
Mar 2nd, 2026
Ginkgo Bioworks launches cloud lab with AI-powered autonomous infrastructure

Ginkgo Bioworks has launched Ginkgo Cloud Lab, a web-based interface allowing researchers to access the company's autonomous laboratory infrastructure remotely. The platform runs on proprietary Reconfigurable Automation Carts, which combine robotic arms, maglev sample transport and industrial software. The Cloud Lab provides access to over 70 instruments covering biological operations including sample preparation, liquid handling and analytical readouts. Its AI-driven agent, EstiMate, enables scientists to submit protocols in natural language and receive immediate compatibility assessments and pricing. The launch supports Ginkgo's 2026 strategy to transition all R&D services to Nebula, its autonomous lab in Boston, and phase out traditional laboratory benches. The company is inviting researchers from academia and biopharmaceutical firms to test the platform at cloud.ginkgo.bio.

Yahoo Finance
Mar 1st, 2026
Ginkgo Bioworks falls 30% despite Invaio peptide crop protection collaboration and $250M cost savings

Ginkgo Bioworks has reported full-year 2025 results showing lower revenue at $170.16 million and a reduced net loss of $312.76 million, alongside announcing a collaboration with Invaio Sciences on peptide-based crop protection. Despite this, shares declined 30.48% in one day to $6.75. The biotech company has achieved $250 million in annual cost savings and maintains a strong balance sheet with $474 million in cash and no bank debt. Analyst estimates suggest the stock is 32.5% undervalued, with a fair value of $10 per share. However, the company faces significant headwinds, with shares down 22.41% year-to-date and 87.86% over three years. Key risks include slower adoption of its AI and automation platform and margin pressure from underutilised laboratory capacity.

Yahoo Finance
Feb 28th, 2026
Ginkgo Bioworks pivots to autonomous labs, plans biosecurity spin-off amid revenue decline

Ginkgo Bioworks has outlined a 2026 strategy centred on autonomous labs, whilst reporting declining cell engineering revenue and improved cash burn. The company will concentrate capital on its Nebula system in Boston, expand capacity towards 100 racks, and commercialise offerings including Solutions, Datapoints and cloud lab services integrated with AI. Cell engineering revenue fell 26% year-on-year in Q4, with full-year revenue of $133 million versus $174 million in 2024. However, R&D and G&A cuts improved losses, reducing cash burn to $171 million for 2025. Management is guiding cash burn of $125–$150 million for 2026. The company plans to spin off its biosecurity business to outside investors whilst retaining a minority stake, freeing capital for autonomous lab investments.